BriaCell Therapeutics (TSE:BCT) has released an update.
BriaCell Therapeutics Corp., a leader in developing novel immunotherapies for cancer care, has announced its participation in the prestigious Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting with a poster presentation. The event aims to shed light on BriaCell’s ongoing research and clinical studies, which are focused on bringing new treatment options to breast and prostate cancer patients.
For further insights into TSE:BCT stock, check out TipRanks’ Stock Analysis page.
